GlassScriptPhysician profile
Matthew M Pontzer
NPI 1598736860
$2,185.32
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.00 · 2020: $76.38 · 2023: $1,517 · 2024: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $305.12 | 2023-2024 | Dyanavel Xr |
| Abbvie INC. | $301.77 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $282.54 | 2023-2024 | Caplyta |
| Lundbeck LLC | $174.68 | 2023-2024 | Rexulti |
| Alkermes, INC. | $169.99 | 2019-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $162.04 | 2023-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $118.18 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $112.91 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $107.22 | 2023-2024 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $85.07 | 2023-2024 | Jornay Pm |
| Corium, LLC | $72.47 | 2023-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $55.78 | 2023 | Quviviq |
| Avion Pharmaceuticals | $48.42 | 2023 | Methylphenidate Hydrochloride |
| Noven Therapeutics, LLC | $36.59 | 2024 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $33.71 | 2023 | Hetlioz, Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $30.82 | 2019-2020 | |
| Allergan, INC. | $29.99 | 2020 | |
| Supernus Pharmaceuticals, INC. | $28.92 | 2023-2024 | Qelbree, Qelbree |
| Sage Therapeutics, LLC | $16.07 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pontzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.